165 LUDLOW AVENUE, NORTHVALE, NJ
Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
To Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
To Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Reports Positive Results from a Pivotal Bioequivalence Study
Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Announces First Shipment of Product from New Facility and Packaging Line
Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Q3
Q2
Q1
FY 2024
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence